1. Effect of calcitriol on bone turnover and osteocalcin in recent-onset type 1 diabetes
- Author
-
Napoli N, Strollo R, Pitocco, D, Bizzarri, C, Maddaloni, E, Maggi, D, Manfrini, S, Schwartz, A, Pozzilli, P, Collaborators, IMDIAB Group, Anguissola, Gb, Astorri, E, Barchetta, Ilaria, Benevento, D, Beretta Anguissola, G, Buzzetti, Raffaella, Capizzi, M, Cappa, M, Cassone Faldetta, Mr, Cavallo, Maria Gisella, Cipolloni, L, Cipponeri, E, Crinò, A, Di Stasio, E, Fioriti, E, Ghirlanda, G, Guglielmi, C, Lauria, A, Matteoli, Mc, Maurizi, Ar, Moretti, C, Napoli, N, Palermo, A, Portuesi, R, Spera, S, Strollo, R, Tuccinardi, D, and Valente, L.
- Subjects
Male ,medicine.medical_treatment ,Bone remodeling ,Endocrinology ,Osteogenesis ,Insulin-Secreting Cells ,Insulin ,Age of Onset ,Vitamin D ,Child ,Multidisciplinary ,biology ,C-Peptide ,Mitochondrial medicine Energy and redox metabolism [IGMD 8] ,Vitamins ,Osteocalcin ,Medicine ,Female ,Collagen ,medicine.drug ,Research Article ,Peak bone mass ,Adult ,medicine.medical_specialty ,Calcitriol ,Adolescent ,Clinical Research Design ,Science ,Bone and Mineral Metabolism ,Bone resorption ,Autoimmune Diseases ,Rheumatology ,Internal medicine ,medicine ,Humans ,Bone Resorption ,Retrospective Studies ,Nutrition ,Glycated Hemoglobin ,Diabetic Endocrinology ,Type 1 diabetes ,Endocrine Physiology ,business.industry ,Diabetes Mellitus Type 1 ,medicine.disease ,Peptide Fragments ,Diabetes Mellitus, Type 1 ,Metabolic control analysis ,biology.protein ,Clinical Immunology ,business ,Follow-Up Studies - Abstract
Contains fulltext : 125353.pdf (Publisher’s version ) (Open Access) BACKGROUND: Vitamin D supplementation in childhood improves the achievement of peak bone mass. We investigated the effect of supplementation with calcitriol on bone turnover in recent-onset type 1 diabetes (T1D). Moreover, the association between osteocalcin and parameters of beta-cell function and metabolic control was examined. METHODOLOGY/PRINCIPAL FINDINGS: We conducted a post-hoc analysis of a double-blind, placebo-controlled study of calcitriol supplementation to preserve beta-cell function. 27 recent-onset T1D subjects, mean age 22 years, were randomized to 0.25 microg calcitriol per day or placebo (1:1) and followed up for one year. Changes in bone formation (osteoclacin) and resorption (beta-CrossLaps) markers, and differences between placebo and calcitriol-treated group were evaluated. At baseline, osteocalcin levels were significantly lower in female than in male patients (P
- Published
- 2012